DermTech: demand to strengthen pharma partnerships over next 5 years

By Melissa Fassbender contact

- Last updated on GMT

DermTech’s patented platform technology support compound advancement through the clinical stages of development.(Image: iStock/Pixtum)
DermTech’s patented platform technology support compound advancement through the clinical stages of development.(Image: iStock/Pixtum)
DermTech, Inc. has announced two new collaborations with pharmaceutical companies and expects more to follow as the demand for personalized, precision medicine increases.

DermTech develops non-invasive gene expression tests to support skin cancer diagnosis, assess inflammatory diseases, and personalize drug treatment.

The company’s technology enables the analysis of skin biopsy samples collected non-invasively using an adhesive patch.

Dr. Burkhard Jansen, Chief Medical Officer at DermTech, told Outsourcing-Pharma.com, “An increasing number of pharma and large biotech partners are recognizing the value Dermtech’s non-invasive gene expression platform offers to their development efforts through molecular dermatology​.”

In Q1 of 2017, the company has added three new “large​” partnerships, Jansen explained.

Existing partners generally add programs and expand the scope of projects after they see the extent of what the platform can offer​,” he added.

The collaborations have generally entailed non-invasive tissue collection and gene expression analyses for various skin conditions, with and without systemic or topical therapeutic intervention.

Per the company's website​, current clinical collaborations include MedImmune, Biogen, and Johnsons & Johnson, among others.

While our pharma relationships expand, we are also seeing increasing interest from small to midsize biotech companies and from NGO partners​,” said Jansen.

We expect the continuing demand for personalized, precision medicine to further strengthen DermTech’s pharma partnerships over the next five years​.”

Related news

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers